Shire and New River: Buying up the Competition
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 57 (Table of Contents)
Published: 1 Mar-2005
DOI: 10.3833/pdr.v2005.i57.707 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
By acquiring the global rights to NRP104, New River Pharmaceuticals' Phase III ADHD treatment, Shire Pharmaceuticals has effectively licensed a successor to its market-leading ADHD drug, Adderall XR#8482; (extended-release mixed amphetamine salts)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS